Injectable Pharmacotherapy for Opioid Use Disorders (IPOD)
Status:
Completed
Trial end date:
2019-05-01
Target enrollment:
Participant gender:
Summary
The aim of this trial is to assess the clinical utility, effectiveness, and cost implications
of treatment for incarcerated offenders with opioid use disorders who are randomly assigned
to one of three treatment conditions to include a depot formulation of naltrexone (XR-NTX, as
Vivitrol®) only (XR-NTX), Vivitrol provided with sessions with a patient navigator (PN)
XR-NTX+PN, and a drug education procedure (ETAU) before being released to the community. This
trial will investigate whether effective medication therapy used in non-incarcerated
populations will also be effective in incarcerated individuals. Empirical evidence
demonstrates that starting treatment before release greatly increases the probability of
successful outcome including reduced alcohol and drug use, increased employment rates, and
reduced recidivism rates.